SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for
the treatment of respiratory tract infections. This has the potential to be a
breakthrough in the future treatment of respiratory infections, including
viruses, bacteria and fungal infections.

"After an intensive research phase, we are very satisfied that the Danish
Medicines Agency (DKMA) considers our documentation positively and has given a
conditional approval to be able to start the study", says Medical Director Glenn
Gundersen. "The conditions that have been communicated are related to additional
safety data and the company is already working on completing the data as
requested. The data will be provided in due time and we believe that the study
can be initiated during the autumn."

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth
Oslo. Our Vison is "Helping the world fighting infections - developing new ways
of eradicating infections and fighting antimicrobial resistance". We are working
to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com.